Clinical Impact of High-dose Intravenous Methylprednisolone for Ten Days in Relapses of Multiple Sclerosis "Treatment of Relapses in Multiple Sclerosis"


Unal A., SUTLAS P. N. , KUSCU D. Y. , Emre U., YAZAR T., Ankarali H. , ...Daha Fazla

NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH, cilt.16, ss.69-74, 2009 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 16 Konu: 2
  • Basım Tarihi: 2009
  • Dergi Adı: NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH
  • Sayfa Sayıları: ss.69-74

Özet

Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, however there is still no clear evidence supporting an optimum therapeutic regime. The high dose (HD) consisted of at least 500 mg/day, but the total dose of intravenous MP administered and the regimen varied among studies. The aim of this study was to assess the improvement following a standard regime of IVMP (1 g/day MP given for 10 days, without tapering) for MS relapses. A second objective was to search baseline predictors of outcome.